News Articles

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

April 9, 2019

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1)EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2)EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)   THOUSAND OAKS, Calif. and BRUSSELS, April…

Read More

Alpharetta biopharma company names board member as interim CEO

April 8, 2019

An Alpharetta company that is working on treatments for eye disease patients has named a member of its board of directors as interim CEO. George Lasezkay succeeds Daniel H. White as chief executive of Clearside Biomedical Inc. (NASDAQ: CLSD). White resigned as president, CEO and as a member of the Clearside board to pursue other…

Read More